Health Kick Podcast: Prescient Therapeutics an emerging global leader in the next generation of personalised cancer therapies.

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. 

In this episode Tim chats to Steven Yatomi-Clarke, CEO of Prescient Therapeutics (ASX:PTX).

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

The company has continued to make solid progress on all fronts, with positive results from the company’s clinical programs underline its position as an emerging global leader in the next generation of personalised cancer therapies.

Tune in to hear Steven discuss the encouraging activity of its targeted therapy PTX-100 program.